Furthermore, HDAC inhibitor CCNU has been shown to sensitize adult GBM to chemotherapy with lomustine via degradation of mut-p53 [139], while another HDAC inhibitor CUDC-101 has been found to enhance mut-p53 degradation leading to sensitization GBM cells to small molecule inhibitors of EGFR [140]. This evidence concerns the gene EGFR and glioblastoma.